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Treatment-related acute myeloid leukaemia (t-AML) is a serious complication of topoisomerase 2 inhibitor therapy and is
characterised by the presence of mixed lineage leukaemia (MLL) rearrangement. By molecular tracking, we were able to show that
MLL cleavage preceded gene rearrangement by 3 months and before the clinical diagnosis of t-AML in a patient with
haemophagocytic lymphohistiocytosis. This is the first report on the sequential detection of the two biomarkers in treatment-related
leukaemogenesis.
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The relationship between topoisomerase 2 (topo 2) inhibitor
therapy and the pathogenesis of treatment-related acute myeloid
leukaemia (t-AML) with rearrangements of the mixed lineage
leukaemia (MLL) gene is now well documented (Felix, 1998; Pui
and Relling, 2002). This type of t-AML tends to have a
myelomonocytic/monoblastic phenotype and rearrangements of
the MLL gene with multiple partners. Cytogenetic analysis has
revealed a median latency from primary disease to t-AML of 24
months (range 10–100 months). In addition to its clinical
importance as an adverse outcome of chemotherapy, t-AML
provides an opportunity to investigate the timing of the molecular
events involved in the pathogenesis of this condition in relation to
the administration of topo 2 inhibitor therapy. We have back-
tracked the molecular events from a t-AML in a child with
Epstein–Barr virus (EBV)-related haemophagocytic lymphohis-
tiocytosis (HLH).
PATIENT AND METHOD
The patient was an 18-month-old boy, diagnosed with EBV-related
HLH, and treated according to the HLH-94 protocol (Henter
et al, 1997) with dexamethasone, intrathecal methotrexate and
intravenous etoposide (150mgm
 2) given twice weekly in the
first 2 weeks and then weekly for 5 weeks (cumulative etoposide
dose: 1.35gm
 2). At 2 months after the start of treatment,
the patient was in complete remission, but by the 6th month
after HLH diagnosis (4 months after treatment ceased), he
presented with jaw swelling and cervical lymphadenopathy.
Bone marrow examination revealed 70% infiltration with myeloid
blasts, confirmed by cytochemistry and immunophenotyping
as monoblastic AML. There was no CNS involvement
by leukaemia. Interphase cytogenetics of the bone marrow
showed a chromosome 9;11 translocation (47, XY, þ8,
t(9;11)(p22;q23)). The patient received induction chemotherapy
(daunorubicin, cytarabine and thioguanine) for his AML according
to the MRC 10th AML trial (Stevens et al, 1998) and achieved
remission. At 5 months after the diagnosis of t-AML, he
was successfully transplanted with non-T-cell-depleted
bone marrow from an HLA-matched unrelated donor, following
conditioning with cyclophosphamide and total body irradia-
tion. He remains in complete remission 28 months post-
transplantation.
We collected serial blood and bone marrow samples at the time
of the patient’s HLH diagnosis, and thereafter at weekly intervals
for 6 weeks, and then again at 3 and 6 months. Prior approval for
the study was obtained from the local research ethics committee.
Genomic DNA extracted from immediately frozen samples was
digested with BamH1 and analysed for etoposide-induced MLL
cleavage (Aplan et al, 1996) and rearrangement, using a 0.74kb
cDNA probe spanning the MLL breakpoint cluster region (BCR).
The DNA was size fractionated by 0.7% agarose gel electrophor-
esis, and blotted onto nylon membranes. MLL cleavage was
detected, after hybridisation overnight at 601C with the
32P-
labelled MLL probe, using real-time autoradiography. Panhandle
PCR method (Felix and Jones, 1998) was also used to analyse the
same serial blood and bone marrow samples for MLL rearrange-
ment.
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We detected no MLL cleavage in any of the peripheral
blood samples obtained up to the appearance of overt t-AML, 6
months after the diagnosis of HLH. However, a 6.7kb MLL
cleavage fragment, identical to that detected when we incubated
the haemopoietic cell line BV173 in vitro with 10mM etoposide
for 6h, was detected in the bone marrow (morphologically
o5% blasts and no circulating blast seen) obtained 3 months
after HLH diagnosis, 1 month after the last dose of etoposide
(cumulative dose: 1.35gm
 2) and 3 months prior to the diagnosis
of overt t-AML. Analysis of Southern blots of the same BamH1-
digested DNA samples revealed two rearranged MLL fragments
(5.6, 18kb), in addition to the 8.3kb germline MLL fragment,
only in the bone marrow obtained at the time of t-AML diagnosis
(Figures 1 and 2). Panhandle PCR confirmed the presence of
MLL rearrangement and the 5.6kb der (11) MLL PCR product
was only detected in the same bone marrow sample (Figure 3).
This was 4 months after HLH therapy was stopped, and
3 months after the detection of MLL cleavage in the bone
marrow.
DISCUSSION
The occurrence of t-AML involving MLL rearrangements
with a latent period of 24–36 months has previously been reported
in HLH (Takahashi et al, 1998; Kitazawa et al, 2001). Based on
the clinical evidence alone, the latent period from the start of
therapy until the diagnosis of overt t-AML in our patient was
only 6 months. However, using molecular tracking, we have
shown prospectively that etoposide-induced MLL cleavage pre-
ceded MLL rearrangement by 3 months, and furthermore,
using the panhandle PCR method, that MLL rearrangement
could only be detected at the diagnosis of t-AML. As no DNA
samples were available to us in the time period between 3 and 6
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Figure 1 Human genomic MLL with BCR and MLL cleavage fragment. Schematic representation of the genomic MLL locus with BamH1 restriction
enzyme sites, the BCR and the etoposide-induced MLL cleavage fragment in this patient. B – BamH1 sites.
M
V 
4−
11
6
M
3
M
BM
2
W
0
D
1
W
2
W
3 
W
4 
W
5
W
3 
M
6 
M
6
W
4
D
Blood
~18 kb
6.7 kb
~5.6 kb
8.3kb
p
r
e
-
M
U
D
Figure 2 Southern blot analysis of serial samples for MLL cleavage and rearrangement. InstantImager bitmap showing the detection of
32P-labelled MLL
probe hybridisation. MLL cleavage fragment (6.7kb) was identified in the bone marrow 3 months after the start of etoposide therapy. MLL rearranged
fragments (5.6, 18kb) and germline BCR fragment (8.3kb) were only detected at the clinical presentation of t-AML. MLL rearrangement resolved with
further chemotherapy prior to the bone marrow transplant. D – day; W – week; M – month, from the diagnosis of HLH; – clinical presentation of t-AML;
BM – bone marrow; MUD – matched, unrelated donor transplant.
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t-AML clone emerged during a period p3 months. Cytogenetic
and provisional sequencing data conclude that the rearrangement
involved AF9 as the partner gene, with nucleotides insertion within
the breakpoint junction (intron 6 of MLL, intron 4 of AF9) of the
fusion gene.
Our results differ from those reported by Megonigal et al
(2000), who detected a leukaemic clone with MLL-GAS7
within 6 weeks of the start of neuroblastoma therapy including
doxorubicin. This was some 15.5 months before the appearance
of clinically overt t-AML. The result that we obtained suggests
that once established, the putative MLL-AF9 leukaemic
clone developed much more rapidly into overt AML as
compared to the MLL-GAS7 clone. It also suggests that partner
sequences in MLL fusion genes could modify the leukaemogenic
process.
As far as we are aware, this is the first case of t-AML in which
MLL cleavage and rearrangement have been detected consecutively
in a patient developing t-AML. Our finding thus suggests that the
two are temporally related, with gene cleavage and DNA processing
prior to translocation, as proposed in the work by Lovett et al
(2001).
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Figure 3 Panhandle PCR on the same samples for the detection of MLL
rearrangement. Gel doc image showing the panhandle PCR product
(5.6kb) after agarose gel electrophoresis. It was only detected in the
patient’s bone marrow 6 months after the start of etoposide therapy.
Negative controls: UL – unligated, H2O – water; BM – bone marrow;
D – day; W – week; M – month, from the diagnosis of HLH.
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